Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Equity Average (2016 - 2025)

Zevra Therapeutics' Equity Average history spans 10 years, with the latest figure at $143.9 million for Q4 2025.

  • For Q4 2025, Equity Average rose 163.0% year-over-year to $143.9 million; the TTM value through Dec 2025 reached $143.9 million, up 163.0%, while the annual FY2025 figure was $97.2 million, 91.39% up from the prior year.
  • Equity Average reached $143.9 million in Q4 2025 per ZVRA's latest filing, up from $125.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $267.0 million in Q1 2022 to a low of -$137.8 million in Q4 2022.
  • Average Equity Average over 5 years is $73.6 million, with a median of $60.9 million recorded in 2023.
  • The largest YoY upside for Equity Average was 2893.75% in 2022 against a maximum downside of 218.1% in 2022.
  • A 5-year view of Equity Average shows it stood at $116.7 million in 2021, then plummeted by 218.1% to -$137.8 million in 2022, then surged by 144.76% to $61.7 million in 2023, then fell by 11.31% to $54.7 million in 2024, then soared by 163.0% to $143.9 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Equity Average are $143.9 million (Q4 2025), $125.2 million (Q3 2025), and $79.1 million (Q2 2025).